~~<i id='B5BA95BF44'><strike id='B5BA95BF44'><tt id='B5BA95BF44'><pre id='B5BA95BF44'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：knowledge 2025-09-28 22:23:08 Page View：9424

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： HPV cancer vaccine study demonstrates efficacy
Next article： Peter Hotez and the public health issue of online harassment

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Aspartame and sugar

AdobeTheInternationalAgencyforResearchonCancer(IARC,anentitywithintheWorldHealthOrganization)recentl

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

YouTube cracks down on misinformation on cancer treatment

JennyKane/APYou’rereadingthewebeditionofSTATHealthTech,ourguidetohowtechistransformingthelifescience